Heterocyclylalkylamines as muscarinic receptor antagonists

A compound of Formula I

• wherein:
• R1, R2 and R3 are independently in each occurrence hydrogen, halogen, (C1-6)-alkyl, —OR′, —SR′, —NR′R″, —SOR′, —SO2R′, —COOR′, —OCOR′, —OCONR′R″, —OSO2R′,—OSO2NR′R″;
• —NR′SO2R″, —NR′COR″, —SO2NR′R″, —SO2(CH2)1-3CONR′R″, —CONR′R″, cyano, haloalkyl, or nitro;
• or R1 and R2 if adjacent, taken together with the carbons to which they are attached may also form a 5- to 7- membered aromatic, saturated or unsaturated ring, optionally incorporating one or two ring heteroatoms chosen from N, S (O)0-2, or O, and optionally substituted with (C1-6)-alkyl, halo, cyano or lower alkoxy;
• R′ and R″ are independently in each occurrence hydrogen, (C1-6)-alkyl, substituted lower alkyl, (C0-3)alkylalkoxy, aryl, heterocyclyl, heteroaryl, aryl-(C1-3)-alkyl, heteroaryl-(C1-3)-alkyl, heterocyclyl-(C1-3)-alkyl, cycloalkylalkyl, cycloalkyl, or R′ and R″ together with the nitrogen they are attached may also form a 5- to 7- membered ring, optionally incorporating one additional ring heteroatom chosen from N, O or S(O)0-2;
• R4 is independently in each occurrence (C1-6) alkyl;
• R5 is independently in each occurrence (C1-6) alkyl, (C1-6) alkenyl, (C1-6) alkynyl, or cycloalkyl;
• one of X, Y or Z is independently S, O, or N—R6, the others are CH2;
• R6 is hydrogen, (C1-6)-alkyl, haloalkyl, aryl(C1-6)alkyl, heteroaryl(C1-6)alkyl, —(C1-6)—CR′R′R′, —COOR′, —SO2R′, —C(O)R′, —SO2(CH2)0-3NR′R″, —CONR′R″, —C(O)OCH2OC(O)R′, —C(O)OCH2SC(O)R′, or —PO(OR′)2, where R′ and R″ are as defined above;
• m is 1;
• n is 3;
• or pharmaceutically acceptable salts or solvates thereof.